Search
Candel Therapeutics Inc
CADLAdd to Watchlist
11.550USD
+0.260+2.30%
Close 09-23 16:00（ET）
846.27MMarket Cap
LossP/E TTM
After-hours 16:26 (ET)11.390USD-0.170-1.47%
After-hours 16:26 (ET)Candel Therapeutics Inc (CADL) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Candel Therapeutics Inc in the past month.
Buy
2 Strong Buy
6 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
21.750USD+92.65%
CADL Analyst Recommendation Trends
In the current month, CADL has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CADL average Analyst price target in the last month is 21.750.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
2
2
2
2
2
2
6
6
6
5
5
5
5
5
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
9
8
8
8
8
8
CADL Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, CADL EPS is projected to reach -0.359 in FY2026Q3, following reported EPS of -0.525 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.25
-0.32
-0.24
-0.36
-0.35
Actual
-0.54
-0.14
-0.52
--
--
Surprise
-118.45%
+55.15%
-121.75%
--
--
FAQs
What is Candel Therapeutics Inc's price target?
Analysts forecast that Candel Therapeutics Inc's price target is USD 21.75, with the highest forecast at USD 29.00 and the lowest forecast at USD 15.00.
How have Candel Therapeutics IncCADL's recent earnings per share performed?
The market expectation was USD -0.52, while Candel Therapeutics IncCADL's earnings per share (EPS) for the previous quarter was USD -0.14. EPS for the next quarter is expected at USD -0.36.
What is the analyst rating for Candel Therapeutics Inc?
Based on the ratings of Candel Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.